Literature DB >> 26773992

Associations of symptoms, neurocognition, and metacognition with insight in schizophrenia spectrum disorders.

Kevin K S Chan1.   

Abstract

Many persons with schizophrenia experience poor insight and, as a result, are at risk for treatment non-adherence and numerous negative outcomes. However, to date, the etiology of poor insight has not yet been fully elucidated. One recent theory concerning the roots of poor insight in schizophrenia has proposed that it may result, in part, from impairments in metacognition, or the capacity to think about thinking. The present study thus aims to examine whether metacognition is associated with insight even after controlling for the effects of psychiatric symptomatology and neurocognition. In this study, 95 adults with a schizophrenia spectrum disorder were assessed on measures of insight (i.e., awareness of symptoms, treatment needs, and illness consequences), psychiatric symptoms (i.e., positive symptoms, negative symptoms, and general psychopathology), neurocognitive functions (i.e., executive function, memory, and attention), and metacognitive capacities (i.e., self-reflectivity and theory of mind). Univariate correlations followed by stepwise multiple regressions, which controlled for symptoms and neurocognition, indicated that both self-reflectivity and theory of mind were significantly linked with awareness of symptoms; theory of mind was linked with awareness of treatment needs; and self-reflectivity was linked with awareness of illness consequences. Importantly, these findings suggest that metacognitive capacities may be related to insight independent of concurrent psychiatric symptoms and neurocognitive deficits. Moreover, awareness of different facets of the illness may require contributions from different components of metacognition. Future research should investigate how existing metacognitive skill training programs could potentially be tailored, or modified, to help persons with schizophrenia to develop and enhance insight.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26773992     DOI: 10.1016/j.comppsych.2015.09.009

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  5 in total

1.  Metacognitive Deficits Predict Impaired Insight in Schizophrenia Across Symptom Profiles: A Latent Class Analysis.

Authors:  Paul H Lysaker; Emily Gagen; Abigail Wright; Jenifer L Vohs; Marina Kukla; Phillip T Yanos; Ilanit Hasson-Ohayon
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

2.  Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments.

Authors:  Paul H Lysaker; Michelle L Pattison; Bethany L Leonhardt; Scott Phelps; Jenifer L Vohs
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

3.  Persons with first episode psychosis have distinct profiles of social cognition and metacognition.

Authors:  M Ferrer-Quintero; D Fernández; R López-Carrilero; I Birulés; A Barajas; E Lorente-Rovira; L Díaz-Cutraro; M Verdaguer; H García-Mieres; J Sevilla-Llewellyn-Jones; A Gutiérrez-Zotes; E Grasa; E Pousa; E Huerta-Ramos; T Pélaez; M L Barrigón; F González-Higueras; I Ruiz-Delgado; J Cid; S Moritz; S Ochoa
Journal:  NPJ Schizophr       Date:  2021-12-09

4.  Relationship Between Cognitive and Clinical Insight at Different Durations of Untreated Attenuated Psychotic Symptoms in High-Risk Individuals.

Authors:  LiHua Xu; Mei Zhang; ShuQin Wang; YanYan Wei; HuiRu Cui; ZhenYing Qian; YingChan Wang; XiaoChen Tang; YeGang Hu; YingYing Tang; TianHong Zhang; JiJun Wang
Journal:  Front Psychiatry       Date:  2021-11-10       Impact factor: 4.157

5.  Males and females with first episode psychosis present distinct profiles of social cognition and metacognition.

Authors:  M Ferrer-Quintero; D Fernández; R López-Carrilero; I Birulés; A Barajas; E Lorente-Rovira; A Luengo; L Díaz-Cutraro; M Verdaguer; H García-Mieres; A Gutiérrez-Zotes; E Grasa; E Pousa; E Huerta-Ramos; T Pélaez; M L Barrigón; J Gómez-Benito; F González-Higueras; I Ruiz-Delgado; J Cid; S Moritz; J Sevilla-Llewellyn-Jones; S Ochoa
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-08       Impact factor: 5.760

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.